REPL · Replimune Group, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $53.14M | $57.88M | $57.84M | $42.97M | $48.00M | $43.45M | $40.44M | $42.85M | $49.10M | $29.48M |
| SG&A | $18.73M | $26.41M | $32.58M | $14.39M | $18.02M | $15.47M | $15.21M | $13.69M | $14.73M | $11.40M |
| Total Operating Expenses | $71.87M | $84.29M | $90.42M | $57.37M | $66.02M | $58.92M | $55.65M | $56.54M | $63.83M | $40.88M |
| D&A | $800.0K | $800.0K | $873.0K | $736.0K | $700.0K | $700.0K | $621.0K | $700.0K | $700.0K | $620.0K |
| Operating Income | ($71.87M) | ($84.29M) | ($90.42M) | ($57.37M) | ($66.02M) | ($58.92M) | ($55.65M) | ($56.54M) | ($63.83M) | ($40.88M) |
| Interest Expense | $1.47M | $1.49M | $1.48M | $1.43M | $1.45M | $1.44M | $1.11M | $1.01M | $955.0K | - |
| Income Tax | ($311.0K) | $0 | $0 | $0 | $575.0K | $0 | $201.0K | $473.0K | $0 | - |
| Net Income | ($70.93M) | ($83.10M) | ($86.69M) | ($53.77M) | ($66.34M) | ($53.05M) | ($49.55M) | ($51.12M) | ($60.04M) | ($42.25M) |
| EPS - Basic | ($0.77) | ($0.90) | ($0.95) | ($0.78) | ($0.79) | ($0.68) | ($0.75) | ($0.77) | ($0.90) | ($0.78) |
| EPS - Diluted | ($0.77) | ($0.90) | ($0.95) | ($0.78) | ($0.79) | ($0.68) | ($0.75) | ($0.77) | ($0.90) | ($0.78) |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $122.95M | $102.30M | $97.37M | $111.12M | $172.25M | $113.49M | $74.46M | $97.67M | $76.00M | $146.59M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $5.65M | $6.40M | $15.48M | $12.46M | $7.19M | $8.41M | $2.58M | $3.90M | $4.37M | $5.36M |
| Current Assets | $280.35M | $333.75M | $413.37M | $495.88M | $547.58M | $442.63M | $433.67M | $479.16M | $508.18M | $592.60M |
| Total Assets | $333.59M | $389.45M | $469.51M | $551.33M | $603.63M | $498.20M | $487.72M | $532.93M | $562.40M | $646.59M |
| Current Liabilities | $50.09M | $52.90M | $59.56M | $62.36M | $47.89M | $43.79M | $40.44M | $38.65M | $39.83M | $33.83M |
| Long-term Debt | $47.63M | $47.21M | $46.79M | $46.38M | $45.96M | $45.57M | $44.81M | $44.43M | $29.16M | $28.65M |
| Total Liabilities | $123.05M | $126.11M | $132.79M | $135.49M | $121.25M | $116.74M | $113.21M | $111.39M | $97.23M | $91.30M |
| Stockholders' Equity | $210.54M | $263.34M | $336.71M | $415.84M | $482.37M | $381.46M | $374.51M | $421.54M | $465.17M | $555.29M |
| Retained Earnings | ($1.19B) | ($1.12B) | ($1.04B) | ($948.58M) | ($874.45M) | ($808.11M) | ($701.28M) | ($646.21M) | ($595.09M) | ($485.49M) |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($77.02M) | ($49.17M) | - | - | ($48.59M) | - | - | ($33.45M) |
| Investing Cash Flow | - | - | $65.05M | $29.77M | - | - | $7.36M | - | - | $5.32M |
| Financing Cash Flow | - | - | ($158.0K) | $96.64M | - | - | $1.10M | - | - | $32.52M |
| CapEx | - | - | $2.74M | $449.0K | - | - | $449.0K | - | - | $1.07M |
| Free Cash Flow | - | - | ($79.76M) | ($49.62M) | - | - | ($49.04M) | - | - | ($34.52M) |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 0.92 | 0.92 | - | - | 0.99 | - | - | 0.82 |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -21.3% | -21.3% | -18.5% | -9.8% | -11.0% | -10.6% | -10.2% | -9.6% | -10.7% | -6.5% |
| Return on equity | -33.7% | -31.6% | -25.7% | -12.9% | -13.8% | -13.9% | -13.2% | -12.1% | -12.9% | -7.6% |
| Return on invested capital | -22.0% | -21.4% | -18.6% | -9.8% | -9.9% | -10.9% | -10.5% | -9.6% | -10.2% | - |
| Liquidity | ||||||||||
| Current ratio | 5.60 | 6.31 | 6.94 | 7.95 | 11.43 | 10.11 | 10.72 | 12.40 | 12.76 | 17.52 |
| Quick ratio | 5.60 | 6.31 | 6.94 | 7.95 | 11.43 | 10.11 | 10.72 | 12.40 | 12.76 | 17.52 |
| Cash ratio | 2.45 | 1.93 | 1.63 | 1.78 | 3.60 | 2.59 | 1.84 | 2.53 | 1.91 | 4.33 |
| Leverage | ||||||||||
| Debt / Equity | 0.23 | 0.18 | 0.14 | 0.11 | 0.10 | 0.12 | 0.12 | 0.11 | 0.06 | 0.05 |
| Debt / Assets | 0.14 | 0.12 | 0.10 | 0.08 | 0.08 | 0.09 | 0.09 | 0.08 | 0.05 | 0.04 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -49.0x | -56.6x | -61.3x | -40.2x | -45.5x | -41.0x | -49.9x | -55.9x | -66.8x | - |
| Equity multiplier | 1.58 | 1.48 | 1.39 | 1.33 | 1.25 | 1.31 | 1.30 | 1.26 | 1.21 | 1.16 |
| Liabilities / Assets | 0.37 | 0.32 | 0.28 | 0.25 | 0.20 | 0.23 | 0.23 | 0.21 | 0.17 | 0.14 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 4.3x | 1.5x | 2.5x | 1.6x | 2.1x | 2.3x | 1.4x | 1.3x | 2.4x | 1.7x |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -8.9% | -43.1% | -57.6% | -3.1% | -16.8% | 7.7% | -36.1% | -35.8% | -53.5% | -49.3% |
| Net income growth (YoY) | -6.9% | -56.6% | -61.2% | -8.5% | -29.8% | 11.6% | -17.3% | -28.8% | -39.3% | -54.7% |
| EPS growth (YoY) | 2.5% | -32.4% | -21.8% | -4.0% | -2.6% | 24.4% | 3.8% | -11.6% | -13.9% | -47.2% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -60.7% | -1.2% | - | - | -42.0% | - | - | -85.6% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -56.4% | -31.0% | -19.0% | 11.0% | 14.4% | -18.0% | -32.6% | -29.2% | 21.1% | 35.0% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Replimune Group against the 5 most active filers in the same SIC group.